Week 51: Promiscuous Drugs - A Good Thing!
BiSpecific Antibodies Showing Promise for Lymphoma Patients
Hello Avatar! Welcome back for another week of biotech analysis. For the next few weeks we will continue our scientific focus going into detail on the most exciting emerging science areas we see for 2022.
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biot…
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.